ADMA — ADMA Biologics, Inc.

ADMA Biologics, Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $510 million for the full year 2025, a 20% increase year-over-year.
• Adjusted EBITDA: $231 million, up 40% year-over-year.
• Adjusted Net Income: $161 million, reflecting a 35% increase year-over-year.
• Fourth Quarter Revenue: $139.2 million, an 18% year-over-year growth.
• Fourth Quarter Adjusted EBITDA: $73.6 million, a 52% increase year-over-year.
• Gross Margin: Expanded to 63.8% in Q4 2025, up from 51.5% in 2024.

2. Strategic Updates and Business Highlights

• Ascentive Growth: Achieved $363 million in net revenue for 2025, a 51% year-over-year growth, with record utilization levels.
• Manufacturing Improvements: Transition to yield-enhanced production is now routine, supporting margin growth.
• Plasma Collection Network: Repositioned to improve efficiency; entered an agreement to monetize three plasma centers while securing long-term supply agreements.
• Leadership Transition: Brad Tade announced his retirement as CFO, with Terry Kohler appointed as the new CFO, focusing on capital efficiency and cash conversion.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to exceed $635 million, with adjusted net income projected to exceed $255 million and adjusted EBITDA over $360 million.
• 2027 Projections: Total revenue expected to exceed $775 million, with adjusted net income over $315 million and adjusted EBITDA exceeding $455 million.
• Long-term Potential: SG001 pipeline asset anticipated to represent a $300 million to $500 million peak annual revenue opportunity.

4. Bad News, Challenges, or Points of Concern

• Working Capital Management: Recent increases in working capital due to accelerated revenue growth; however, improvements in accounts receivable and days sales outstanding are expected in 2026.
• Market Penetration: While Ascentive is showing strong growth, the company acknowledges that it is still early in its penetration curve within its total addressable market.
• Dependence on Plasma Supply: The company is reliant on high-titer plasma supply, which poses risks if collection does not meet demand.

5. Notable Q&A Insights

• Ascentive Product Mix: The current mix is approximately 70% Ascentive and 30% Bivigam, with expectations for continued growth in Ascentive's share.
• McKesson Distribution Agreement: Anticipated to enhance revenue and improve receivables normalization, with expected impacts materializing in the latter half of 2026.
• Third-Party Supply Agreements: Ongoing efforts to secure additional plasma supply are progressing well, with expectations of expanding the network of collection centers.

Overall, ADMA Biologics is entering 2026 with strong financial momentum and strategic initiatives aimed at sustaining growth, despite some challenges in working capital and market penetration.